ライフサイエンスコーパス: CTGF

1 CTGF and integrin alphavbeta6 are potential therapeutic

2 CTGF and integrin alphavbeta6 proteins were highly expre

3 CTGF and integrin alphavbeta6 regulate oval cell activat

4 CTGF associated nominally with CKD (HR, 0.83; 95% CI, 0.

5 CTGF can affect EMD- and TGF-beta1-induced PDL cell prol

6 CTGF has been proposed to function as a critical TGF-bet

7 CTGF inhibition downregulated both EMD- and TGF-beta1-in

8 CTGF is a cytokine overexpressed in the intestine of pat

9 CTGF is also involved in the tumor microenvironment in m

10 CTGF is cleaved in vivo into distinct domains.

11 CTGF KD MSCs differentiated into adipocytes at a sixfold

12 CTGF KD MSCs exhibited fivefold lower proliferation comp

13 CTGF labels up to two-thirds of NEUN+ cells in the subpl

14 CTGF overexpression, under nonstimulatory conditions, do

15 CTGF pretreatment of astrocytes increased their expressi

16 CTGF protein expression was evident by day 3 of AngII ex

17 CTGF silencing also decreased the expression of SPARC, p

18 CTGF SNPs do not influence the rate of recurrence after

19 CTGF treatment increases the number of immature beta-cel

20 CTGF treatment upregulates positive cell-cycle regulator

21 teins including TGF-beta1, alpha-SMA, PAI-1, CTGF, FN and collagen-1.

22 Genotyping was performed for 4 CTGF SNPs (rs9402373, rs12526196, rs6918698, and rs93990

23 with thrombospondin repeat 7 (ADAMTS7) as a CTGF binding protein.

24 Overexpression of a CTGF plasmid lacking the 3'-UTR and administration of re

25 h factor-beta-induced collagen accumulation, CTGF, and PAI-1 expression, but enhances Smad7 protein e

26 in-1, collagen I, alpha-smooth muscle actin, CTGF, and PAI-1, but decreased Smad7 expression.

27 In addition, CTGF contributes to fibrocyte proliferation in the myoca

28 ecombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis.

29 of blocking antibodies specifically against CTGF domain 4 or recombinant Dickkopf-related protein-1,

30 eta1 (transforming growth factor-beta-1) and CTGF (connective tissue growth factor), reduced fibrobla

31 levels of renin, angiotensinogen, IL-18 and CTGF.

32 alphaSMA, EDA-fibronectin, collagen 1A, and CTGF.

33 don cells were stimulated with IL-1beta, and CTGF and significantly higher in CD146(+) TSCs than CD14

34 Aldosterone and CTGF increased lysyl oxidase, and aldosterone enhanced m

35 stream target genes, for example, ANKRD1 and CTGF.

36 ed TGF (transforming growth factor)-beta and CTGF (connective tissue growth factor) levels.

37 ), which modulate nuclear factor binding and CTGF production, and a smad3 SNP (rs17293632) involved i

38 iven by factors including TGF-beta, BMPs and CTGF.

39 TGF-beta1, COL1A1, and CTGF expression was inhibited by Stattic or dominant-neg

40 eading to increased TGF-beta1, collagen, and CTGF production in ileal strictures.

41 rtices from diabetic mice (both CTGF +/+ and CTGF +/-) manifested higher expression of CTGF and throm

42 glucose levels were increased in CTGF+/+ and CTGF+/- mice (28.2 3.3 mmol/L vs 27.0 3.1 mmol/L), plasm

43 ere similar between non-diabetic CTGF+/+ and CTGF+/- mice.

44 n-responsive genes including ATF3, CYR61 and CTGF, all of which have been implicated in human hypospa

45 alpha-smooth muscle actin, fibronection, and CTGF, markers of myofibroblastic activation of HSCs.

46 ted with and without TGF-beta inhibitor, and CTGF protein levels were assayed by Western blot analysi

47 ation of bone morphogenic protein 4 mRNA and CTGF mRNA (inhibitors of OPC differentiation) and the do

48 The Smad2 phosphorylation and CTGF induction required signaling via both the TGFbeta-r

49 Both SCM and CTGF inhibited the differentiation of purified rat oligo

50 beta-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively),

51 Fbeta2-induced upregulation of alpha-SMA and CTGF.

52 e in collagen I, fibronectin 1, TGFbeta, and CTGF mRNA in Ctr but not in betaRM hearts.

53 ocin-induced diabetes in wild type (+/+) and CTGF heterozygous (+/-) mice.

54 Anti-CTGF reversed the SCM-mediated effects on myelination.

55 Furthermore, treatment with BQ123 or an anti-CTGF antibody attenuated alpha-SMA expression induced by

56 FG-3019, an anti-CTGF monoclonal antibody, was used to inhibit CTGF.

57 fer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and

58 Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect

59 y SMC and smLRP1(-/-) main pulmonary artery (CTGF and NOX4) and reversed PAH in smLRP1(-/-) mice.

60 erone, specifically RhoA activity as well as CTGF, lysyl oxidase, and microRNA-21 expression.

61 m signaling molecules, including c-myc, axl, CTGF, cyr61 and survivin and upregulation of the tumor g

62 Cortices from diabetic mice (both CTGF +/+ and CTGF +/-) manifested higher expression of C

63 entiation of CD146+ stem/progenitor cells by CTGF delivery successfully led to tendon regeneration wi

64 CTGF expression in human BM-derived MSCs by CTGF short hairpin RNA.

65 the OC compartment, where its absence causes CTGF accumulation, leading to increased OC activation an

66 TEA domain-dependent transcription and CCN2/CTGF expression.

67 rowth factor-beta-induced expression of CCN2/CTGF and periostin.

68 Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in inj

69 YAP target gene (CCNE1, CTGF, Cyr61) mRNA expression was also increased in the t

70 Clinically, CTGF expression correlates with tumor progression and is

71 Colon expression of COL1A1, CTGF, alpha-SMA and COX-2 did not differ between TNBS ra

72 After being cultured, CTGF was increased in fibrocytes from patients with COA,

73 CYR61-CTGF-NOV (CCN)1 is a dynamically expressed extracellular

74 1, a matricellular protein of the CCN (CYR61/CTGF/NOV) family, is accumulated in hepatocytes of human

75 eted matricellular protein of the CCN (CYR61/CTGF/NOV) family, is significantly downregulated in clin

76 adenoviral system in vitro led to decreased CTGF expression and reduced proliferation and Transwell

77 cific knockdown of Smad3 partially decreases CTGF production, whereas it has no significant influence

78 by connective tissue growth factor delivery (CTGF delivery) in the early phase of tendon healing, fol

79 In vitro characterization demonstrated CTGF binding and processing by ADAMTS7.

80 activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proli

81 th (PICP, ICTP, MMP-2, TGF-beta1, desmosine, CTGF, TIMP-1).

82 Plasma creatinine was higher in diabetic CTGF+/+ group (11.7+/-1.2 vs 7.9+/-0.6 micromol/L p<0.01

83 mesangial expansion were reduced in diabetic CTGF+/- animals.

84 rol levels were similar between non-diabetic CTGF+/+ and CTGF+/- mice.

85 f MRTF-induced transcription also diminished CTGF expression and fibrosis in the peritoneal fibrosis

86 Early CTGF expression occurred before fibrocyte migration (1 d

87 ered in the scaffolds by spatially embedding CTGF- or TGFbeta3-encapsulated microspheres (microS) to

88 We discovered that in embryos CTGF is necessary for beta-cell proliferation, and incre

89 The results provide novel insights into EMD-CTGF interaction in PDL cells.

90 AM-1 and the connective tissue growth factor CTGF.

91 Connective tissue growth factor (CTGF or CCN2) is a matricellular protein expressed by mu

92 vealed that connective tissue growth factor (CTGF) aggravates the fibrotic environment and drives can

93 YAP and TAZ connective tissue growth factor (CTGF) and Cyr61 target genes, and exhibit anchorage-inde

94 s proteins, connective tissue growth factor (CTGF) and TGF-beta1, in UUO kidney.

95 to produce connective tissue growth factor (CTGF) and then resulted in accumulation of ECM of BUMPT

96 Connective tissue growth factor (CTGF) and transforming growth factor beta 3 (TGFbeta3) w

97 nsisting of connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF).

98 identified connective tissue growth factor (CTGF) as a novel target of miR-145 in glioma cells; tran

99 , we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma.

100 alpha1, and connective tissue growth factor (CTGF) gene expression was measured by quantitative RT-PC

101 one induced connective tissue growth factor (CTGF) in the absence but not in the presence of cortisol

102 Delivery of connective tissue growth factor (CTGF) into full-transected rat patellar tendons signific

103 Connective tissue growth factor (CTGF) is a downstream mediator of TGF-beta.

104 Connective tissue growth factor (CTGF) is a key mediator of tissue fibrogenesis in kidney

105 Connective tissue growth factor (CTGF) is a matricellular protein that mediates cell-matr

106 Connective tissue growth factor (CTGF) is a multifunctional secreted protein that acts as

107 Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role

108 Connective tissue growth factor (CTGF) is an important mediator of fibrosis; emerging evi

109 otic liver, connective tissue growth factor (CTGF) is constantly expressed in activated hepatic stell

110 In mice, connective tissue growth factor (CTGF) is expressed in embryonic beta-cells and in adult

111 Connective tissue growth factor (CTGF) is highly expressed in MSCs, but its role in the B

112 Connective tissue growth factor (CTGF) is important for OC activation and contributes to

113 Connective tissue growth factor (CTGF) is known to regulate fibroblast activities.

114 ted protein connective tissue growth factor (CTGF) is upregulated in response to cardiac injury or wi

115 . show that connective tissue growth factor (CTGF) regulates a multicellular signaling cascade determ

116 protein for connective tissue growth factor (CTGF) than OECs.

117 Connective tissue growth factor (CTGF) up-regulation induced by aldosterone was prevented

118 in POH, and connective tissue growth factor (CTGF) was overexpressed in all types of LVH.

119 Connective tissue growth factor (CTGF), a direct target of miR-133b, is crucial in the du

120 identified connective tissue growth factor (CTGF), a matricellular protein that is highly expressed

121 Connective tissue growth factor (CTGF), a matrix-associated protein with four distinct cy

122 icates that connective tissue growth factor (CTGF), a multifunctional signaling modulator, promotes c

123 synthesis, connective tissue growth factor (CTGF), and alpha-smooth muscle actin gene expression at

124 61 (CYR61), connective tissue growth factor (CTGF), and ankyrin repeat domain 1 (ANKRD1).

125 , including connective tissue growth factor (CTGF), and cysteine-rich angiogenic inducer 61 (CYR61).

126 scle actin, connective tissue growth factor (CTGF), and plasminogen activator inhibitor (PAI-1).

127 target CCN2/connective-tissue growth factor (CTGF), as well as anchorage-independent growth, capacity

128 to express connective tissue growth factor (CTGF), driving fibroblast proliferation in a paracrine f

129 GF-betaR1), connective tissue growth factor (CTGF), E-cadherin, SRY-box 7 (SOX7), and NFAT (nuclear f

130 , including connective tissue growth factor (CTGF), fibronectin, and collagens Col1a1, Col3a1, Col6a3

131 18 (IL-18), connective tissue growth factor (CTGF), neutrophil gelatinase-associated lipocalin, and k

132 TGF-beta1), connective tissue growth factor (CTGF), procollagen I carboxy-terminal propeptide (PICP),

133 oduction of connective tissue growth factor (CTGF).

134 /TAZ target connective tissue growth factor (CTGF).

135 uron marker connective tissue growth factor (CTGF).

136 yclin A and connective tissue growth factor (CTGF).

137 ecretion of connective tissue growth factor (CTGF).

138 so known as connective tissue growth factor (CTGF)], markers of epithelial to mesenchymal transition,

139 1/2 acts on connective tissue growth factor (CTGF/CCN2) expression to mediate the myocardial fibrosis

140 Myocardial connective tissue growth factor (CTGF/CCN2) is induced in heart failure, a condition asso

141 dicate that connective tissue growth factor (CTGF/CCN2) stimulates chondrocyte proliferation and matu

142 tricellular connective tissue growth factor (CTGF/CCN2).

143 ing protein connective tissue growth factor (CTGF/CCN2).

144 ular genes (connective tissue growth factor [CTGF], secreted protein, acidic and rich in cysteine), c

145 ly known as connective tissue growth factor, CTGF) using a specific antibody (termed FG-3019 or pamre

146 s suggest that ADAMTS7 is a new protease for CTGF protein and a novel regulator in the OC compartment

147 irst time that the ETAR pathway is vital for CTGF expression, which results in fibrocyte differentiat

148 In cultured MEF from CTGF+/+ mice, glucose (25 mM) increased expression of pr

149 anscriptional activation of its target gene, CTGF.

150 in the expression of the YAP-regulated genes CTGF and CYR61 induced by HLA I stimulation.

151 ad and neck squamous cell carcinoma (HNSCC), CTGF promotes the MET and reduces invasiveness.

152 However, CTGF mildly altered the overall cardiac response to TGF-

153 fa overexpression or local delivery of human CTGF recombinant protein accelerated bridging and functi

154 iomyocytes pretreated with recombinant human CTGF (rec-hCTGF) revealed marked reduction of both beta(

155 tment of whole islets with recombinant human CTGF induces beta-cell replication and gene expression c

156 MSR1, MYOM3, and COX17), 2 hypomethylated ( CTGF and MMP2); and 2 microRNA: 1 hypermethylated (miR-2

157 and fibrocytes expressing CD45, collagen I, CTGF, ETAR, or alpha-SMA were identified by flow cytomet

158 We therefore examined if CTGF inhibition has anti-fibrotic effects in PF.

159 g by TNFalpha/IFNgamma and TNFalpha/IFNgamma/CTGF exposure respectively), compared with bone marrow-d

160 /+ animals; this reduction was attenuated in CTGF+/- group.

161 hese genes by high glucose was attenuated in CTGF+/- MEF.

162 6 expression was significantly attenuated in CTGF-delivered tendon healing.

163 n intervertebral disc led to the decrease in CTGF expression.

164 Leptin was found to be highly expressed in CTGF KD EXM-BM and in BM samples of patients with acute

165 trix metalloproteinase (MMP)-3 expression in CTGF-delivered tendon was organized along with the reori

166 Corroborating a mechanism of GRK5 in CTGF-mediated control of beta-AR sensitivity, Chinese ha

167 ific Tsc1 deletion results in an increase in CTGF secretion that non-cell autonomously stunts oligode

168 ate, plasma glucose levels were increased in CTGF+/+ and CTGF+/- mice (28.2 3.3 mmol/L vs 27.0 3.1 mm

169 L), plasma triglyceride levels were lower in CTGF+/- mice than in CTGF+/+ (0.7 0.2 mmol/L vs 0.5 0.1

170 Expression of nephrin was reduced in CTGF +/+ animals; this reduction was attenuated in CTGF+

171 de levels were lower in CTGF+/- mice than in CTGF+/+ (0.7 0.2 mmol/L vs 0.5 0.1 mmol/L, p<0.05), but

172 Thus, genetic variability in CTGF expression directly modulates the severity of diabe

173 y for beta-cell proliferation, and increased CTGF in beta-cells promotes proliferation of immature (M

174 e, whereas the RhoA activator CN03 increased CTGF expression.

175 lial cells responded to AngII with increased CTGF production (2.1-fold and 2.8-fold, respectively; P

176 nhibition did not attenuate IL-1beta-induced CTGF mRNA expression in healthy or diseased tendon cells

177 HSD2 siRNA abolished the aldosterone-induced CTGF up-regulation.

178 Activation of mesothelial cell LPA1 induced CTGF expression by inducing cytoskeleton reorganization

179 tin is induced by angiotensin II and induces CTGF in cardiomyocytes.

180 TGF monoclonal antibody, was used to inhibit CTGF.

181 Studies in vivo demonstrate that inhibiting CTGF/CCN2 using a specific antibody decreases myocardial

182 R responsiveness in cardiomyocytes involving CTGF-mediated regulation of GRK5.

183 Therefore, we knocked down (KD) CTGF expression in human BM-derived MSCs by CTGF short h

184 5) downstream signaling molecule to mediate CTGF expression.

185 induces matrix metalloproteinase-3-mediated CTGF cleavage, resulting in VEGF release and MSC endothe

186 nvolvement of Stat3 activation in modulating CTGF production upon TGF-beta challenge in activated HSC

187 c minipumps (2.0 mug/kg per min), myocardial CTGF mRNA peaked at 6 hours (21-fold; P < 0.01), whereas

188 so, neither heart-specific Ctgf deletion nor CTGF overexpression altered cardiac remodeling and funct

189 l obstruction in vivo Therefore, domain 4 of CTGF and the WNT signaling pathway are important new tar

190 In this study, we tested the ability of CTGF to promote beta-cell proliferation and regeneration

191 signaling, leading to altered activation of CTGF/CCN2 to mediate fibrosis and alter cardiac function

192 Coexpression of CTGF and the pluripotency genes was found to be associat

193 Genetic deletion of CTGF from neurons, in turn, mitigates the TSC-dependent

194 High dose of CTGF/TGFbeta3-microS (100 mg microS/g of scaffold) showe

195 viscosity was achieved with the high dose of CTGF/TGFbeta3-microS compared with the low-dose and empt

196 Similarly, a high dose of CTGF/TGFbeta3-microS yielded significantly higher collag

197 The effect of CTGF and EMD on osteoblastic mRNA expression in PDL cell

198 empty microS, suggesting the dose effect of CTGF and TGFbeta3 on fibrocartilage formation.

199 To study the effect of CTGF on engraftment of leukemia cells into BM, an in viv

200 The effect of CTGF on isolated fibrocytes suggested a role in fibrocyt

201 of SPARC abrogated the inhibitory effect of CTGF silencing on cell migration.

202 ntagonist (BQ788), reduced the expression of CTGF and alpha-SMA in fibrocytes and fibrocyte different

203 we comprehensively discuss the expression of CTGF and its regulation, oncogenic role, clinical releva

204 nd CTGF +/-) manifested higher expression of CTGF and thrombospondin 1 (TSP1).

205 with this miRNA decreased the expression of CTGF as determined by Western blot analysis and the expr

206 significantly up-regulated the expression of CTGF, a potent profibrotic cytokine.

207 of astrocytes increased their expression of CTGF, suggesting that this inhibitory factor can be posi

208 nduced a concentration-dependent increase of CTGF protein expression in PDL cells.

209 The induction of CTGF by PAR2-AP was synergistically increased when combi

210 hese findings suggest that the inhibition of CTGF by FG-3019 might be a novel treatment for PF throug

211 Mechanistically, inhibition of CTGF decreased invasion and migration associated with re

212 Genetic inhibition of CTGF in human melanoma cells is sufficient to significan

213 Only myofiber-selective inhibition of CTGF protected delta-sarcoglycan-null ( Sgcd(-/-)) mice

214 Knockdown of CTGF in TW2.6 cells was shown to reduce tumor formation

215 lower for infants with detectable levels of CTGF than for those with CTGF levels below the level of

216 Remarkably, neither gain nor loss of CTGF in the heart affected cardiac pathology and propens

217 Again, genetic modulation of CTGF in muscle was not sufficient to drive fibrosis, but

218 fibrosis was also unchanged by modulation of CTGF levels in the heart with aging, pressure overload,

219 ce with cardiac-restricted overexpression of CTGF (Tg-CTGF) or cardiomyocytes pretreated with recombi

220 tissue-specific inducible overexpression of CTGF by kidney pericytes and fibroblasts had no bearing

221 tes in bronchial walls and overexpression of CTGF in fibrocytes from patients with COA.

222 transgenic muscle-specific overexpression of CTGF.

223 and hyperproliferative on overexpression of CTGF.

224 st resulted in Smad2-dependent production of CTGF by resident cells (6 hours), well before the accumu

225 cardiac fibroblasts and the up-regulation of CTGF and fibronectin.

226 collidine in mice, led to down-regulation of CTGF expression and OC proliferation.

227 e investigate whether miR-133b regulation of CTGF influences HCC cell proliferation and migration, an

228 ese results show that miR-133b regulation of CTGF is a novel mechanism critical for the proliferation

229 Production and release of CTGF in culture medium were significantly augmented in h

230 This study investigated the role of CTGF and integrin alphavbeta6 in hepatic progenitor/oval

231 of fibrosis, the cell type-dependent role of CTGF in dystrophic muscle has not been elucidated.

232 Here, we investigated the role of CTGF in fibrogenic cells.

233 cells, the data suggest an important role of CTGF in MSC differentiation into adipocytes and of lepti

234 To study the role of CTGF in PDL development, cells were treated with CTGF in

235 present study, we characterized the role of CTGF in promoting fibrocyte accumulation and regulation

236 To further ascertain the role of CTGF in responses to high glucose, we assessed the conse

237 findings suggest anti-inflammatory roles of CTGF-stimulated TSCs that are likely associated with imp

238 Similarly, we found that silencing of CTGF decreased the migration of glioma cells.

239 Significantly, an exogenous source of CTGF was able to rescue the cell proliferation defect in

240 and cholangiocytes were the main sources of CTGF and integrin alphavbeta6 during liver injury induce

241 l mass reaches 50% recovery after 4 weeks of CTGF treatment, primarily via increased beta-cell prolif

242 explore the effects of EMD and TGF-beta1 on CTGF expression, cells were treated with and without TGF

243 explores the effects of EMD and TGF-beta1 on CTGF in periodontal ligament (PDL) fibroblasts and their

244 was detected only when treated with CTGF or CTGF and IL-1beta that is significantly higher in CD146(

245 F via activation of the Hsp90 /Smad3 and p53/CTGF axis.

246 e via the activation of Hsp90 /Smad3 and p53/CTGF axis.

247 In parallel, CTGF delivery significantly reduced the number of iNOS(+

248 Levels of peritoneal CTGF expression were increased by CG challenges, and sup

249 ular, COL1A1, COL1A2, COL3A1, COL5A1, POSTN, CTGF, LOX, TGFbeta1, PDGFRA, TNC, BGN, and TSP2 were sig

250 Rho kinase inhibition by Y-27632 prevented CTGF and hydroxyproline, whereas the RhoA activator CN03

251 and accompanied by enhanced TGFbeta1-pSmad3-CTGF signaling and increased TGFbeta1-induced PASMC prol

252 the 3'-UTR and administration of recombinant CTGF protein abrogated the inhibitory effect of miR-145

253 h sacubitril/valsartan and valsartan reduced CTGF expression in the remote myocardium, although only

254 apamycin (mTOR) pathway in neurons regulates CTGF production and secretion, revealing a paracrine mec

255 t the FAK/ERK1/2 signaling pathway regulates CTGF-induced proliferation and differentiation of CD146+

256 mad signaling plays major role in regulating CTGF production, TGF-beta stimulated CTGF expression in

257 at a threefold higher rate in adipocyte-rich CTGF KD MSC-derived EXM-BM than in control EXM-BM.

258 In HNSCC patient samples, CTGF expression was positively correlated with the level

259 ransgenic mice with inducible heart-specific CTGF overexpression, mice with heart-specific expression

260 To confirm that muscle-specific CTGF functions to mediate collagen organization, we gene

261 ulating CTGF production, TGF-beta stimulated CTGF expression in activated HSCs is only in part depend

262 EMD- and TGF-beta1-stimulated CTGF expression was significantly reduced in the presenc

263 EMD stimulates CTGF expression in human PDL cells, a process modulated

264 initiation and progression, thus suggesting CTGF as a novel target for PDAC treatment.

265 mited renal fibrosis by directly suppressing CTGF.

266 regulates glioma cell migration by targeting CTGF which downregulates SPARC expression.

267 ardiac-restricted overexpression of CTGF (Tg-CTGF) or cardiomyocytes pretreated with recombinant huma

268 Finally, Tg-CTGF mice subjected to chronic exposure (14 days) to iso

269 e upregulated in both cardiomyocytes from Tg-CTGF mice and cardiomyocytes exposed to rec-hCTGF.

270 ropic responses of myocardial fibers from Tg-CTGF mice and nontransgenic littermate control (NLC) mic

271 sistently, ventricular muscle strips from Tg-CTGF mice stimulated with isoproterenol displayed attenu

272 ioglitazone inhibited the canonical TGFbeta1-CTGF axis in human pulmonary artery SMC and smLRP1(-/-)

273 (smLRP1(-/-)) in mice disinhibited TGFbeta1-CTGF (connective tissue growth factor) signaling, leadin

274 tion is mediated by a FOXO1 induced TGFbeta1/CTGF axis.

275 and Western blot analysis demonstrated that CTGF-induced expression of IL-10 and TIMP-3 in CD146(+)

276 h those observed in vivo, demonstrating that CTGF acts directly on islets to promote beta-cell replic

277 Moreover, we found that CTGF enhances the stem-like properties of HNSCC cells an

278 We also found that CTGF regulates its own expression via TGF-beta signaling

279 Herein, we propose that CTGF is a promising cancer therapeutic target that could

280 Our study reveals that CTGF is necessary and sufficient to stimulate glial brid

281 itoneal mesothelial cells (PMCs) showed that CTGF blockade suppressed TGF-beta1-induced fibroblast pr

282 Mechanistic studies showed that CTGF induces c-Jun expression through alphavbeta3 integr

283 the body, although our results suggest that CTGF is of minimal importance and is an unlikely therape

284 Collectively, our data suggest that CTGF regulates proliferation as a mediator of the canoni

285 and a smad3 SNP (rs17293632) involved in the CTGF pathway.

286 agonists reduced the aldosterone but not the CTGF effect.

287 Thus, CTGF can induce replication of adult mouse beta-cells gi

288 bind to CTGF mediating oval cell adhesion to CTGF and fibronection substrata and promoting transformi

289 Finally, integrin alphavbeta6 could bind to CTGF mediating oval cell adhesion to CTGF and fibronecti

290 The total CTGF production induced by TGF-beta in activated HSCs is

291 evidence link changes in plasma and urinary CTGF levels to diabetic kidney disease.

292 vely studied the association between urinary CTGF (CTGFu) levels and renal allograft fibrosis during

293 Accordingly, we aimed to investigate whether CTGF could play a mechanistic role in regulation of beta

294 s of the deleterious effects associated with CTGF in MD and acutely injured skeletal muscle.

295 s (MSCs) for 6 wk, 3D-printed scaffolds with CTGF/TGFbeta3-microS resulted in a heterogeneous fibroca

296 neous modulus was significantly smaller with CTGF/TGFbeta3-microS than empty microS.

297 etectable levels of CTGF than for those with CTGF levels below the level of detection.

298 in PDL development, cells were treated with CTGF inhibitor.

299 pression was detected only when treated with CTGF or CTGF and IL-1beta that is significantly higher i

300 was expressed in CD146(+) TSCs at 1 wk with CTGF, in contrast to control with no TIMP-3 expression.